1. Helps to stabilize or increase the haemoglobin levels in most patients during the maintenance therapy.
  2. Results in a low need for blood transfusion during treatment and a low rate of breakthrough haemolysis.
  3. Improves the patient’s quality of life and reduces fatigue.

⇒Therapeutic Indications:

Eculizumab is indicated for the treatment of patients with:

•Paroxysmal nocturnal haemoglobinuria (PNH).

•Atypical haemolytic uremic syndrome (aHUS)


Eculizumab is supplied as a concentrate for solution for infusion as a 300 mg vial.

For any medical enquiry,

Contact us at  +91 9591736262 or Email us at